USPTO Director Waives Deadline for Review of Patent Challenge Decisions

WASHINGTON, D.C. – The U.S. Patent and Trademark Office (USPTO) late Monday issued a precedential order that waives the 30-day deadline for parties to request a Director Review of a Patent Trial and Appeal Board (PTAB) decision to institute a patent challenge. The move provides significantly more flexibility for the USPTO Director to review and potentially overturn the PTAB's initial decisions in high-stakes patent validity disputes.

The order, issued by USPTO Director Kathi Vidal, designates a prior sua sponte (on her own initiative) Director Review order as binding precedent. This formalizes a policy that allows the Director to initiate a review of an institution decision at any time before the PTAB issues its final written decision in an inter partes review (IPR) proceeding. It also effectively eliminates the previous 30-day window for patent owners or challengers to file their own requests for such a review, extending that window indefinitely until the case concludes.

For small and mid-sized businesses, this seemingly technical procedural change introduces a new layer of strategic complexity and financial uncertainty into patent litigation. While large corporations have entire legal departments to navigate these shifts, a smaller company's core value can often be tied up in a single patent portfolio. An IPR challenge is a direct, and often costly, assault on that core asset. The waiver of the 30-day deadline means the period of ambiguity is now extended, potentially for the full year or more that an IPR proceeding takes. This prolonged uncertainty can complicate capital raising, deter potential acquirers, and make financial forecasting more difficult.

In our experience, this kind of regulatory fluidity underscores the need for proactive planning. Business owners can no longer treat patent litigation as a siloed legal issue; it has direct and immediate financial consequences. The potential for a PTAB decision to be revisited months after the fact requires a more dynamic approach to budgeting for legal costs and assessing asset valuation. This is a clear example of where robust financial risk management becomes critical. Companies must be able to model the potential costs and value implications of these extended timelines. The expert team at C&S Finance Group LLC helps business leaders navigate these exact challenges, ensuring their financial strategies are resilient enough to withstand unpredictable regulatory shifts. To learn more, visit us at csfinancegroup.com.

Inter partes review is a trial-like proceeding conducted by the PTAB where third parties can challenge the validity of an issued U.S. patent. The process begins with a petitioner filing a request for IPR. The PTAB then reviews the petition and decides whether to "institute" a trial. An institution decision signifies that the challenger has shown a reasonable likelihood of prevailing on at least one of the challenged patent claims. This initial decision is a critical turning point that often pressures patent owners into settling.

The Director Review mechanism was formally established following the Supreme Court's 2021 decision in United States v. Arthrex, which held that the structure of the PTAB was unconstitutional. To remedy this, the Court gave the USPTO Director the authority to review, and potentially reverse, final PTAB decisions. Director Vidal has since expanded the use of this authority to include the review of preliminary decisions, such as the decision to institute a trial, to ensure consistency and correct potential errors early in the process.

By making this deadline waiver precedential, the Director solidifies her office's oversight power. The previous 30-day deadline was a strict one, and parties that missed it lost their opportunity to request a review. Now, a patent owner who initially decides against seeking review of an institution decision can change their mind later in the proceeding if new issues arise. Conversely, a patent challenger who was only partially successful in their petition—for instance, if the PTAB instituted review on some challenged claims but not others—also has more time to seek review of the partial denial.

The primary consequence for businesses involved in patent disputes is the impact on certainty and litigation strategy. For a patent owner, typically the defendant in an IPR, the threat of an unfavorable institution decision now lingers longer. Even if they feel the PTAB's reasoning is flawed, the extended timeline for review could mean months of additional legal costs and business disruption. For a patent challenger, the increased flexibility could be advantageous, offering more time to craft a compelling argument for Director Review.

Legal practitioners and businesses involved in intellectual property will be closely watching how this new precedent is applied. The frequency with which the Director accepts these later-filed review requests will determine the true impact of the rule change. If such reviews become common, it could fundamentally alter the strategic calculations for both patent holders and those challenging their validity before the PTAB.